Detecting Low-Abundance Biomarkers in Blood and CSF: Challenges and Solutions
High-sensitivity biomarker platforms are revolutionizing clinical neuroscience, but significant challenges remain. The blood-brain barrier, complex matrices, and the ultra-low abundance of biomarkers such as mutant huntingtin and amyloid-beta often limit the precision of early disease detection and therapeutic monitoring.
In this vodcast, two biomarker experts delve into practical solutions using ultra-sensitive technologies and validated workflows that are advancing precision medicine in neuroscience.
What You'll Learn:
Ideal for translational scientists, biomarker leads, and clinical development teams, this Expert Talk offers actionable insights to improve biomarker strategies in neurodegenerative disease trials.
Meet the Experts:
Elizabeth van der Kam, SVP Global Translational Biomarkers
Barbara Baldo, Group Leader, Translational Biomarkers
Offered Free by: Evotec International GmbH
See All Resources from: Evotec International GmbH





